A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1385 | Th1061 | Trastuzumab | Light chain 1: DIQMT Full view | 1364 | IIa | Cancer | Herceptin | Genentech | Sterile, white to pale yellow, preservative-free lyophilized powder |  Intravenous administration | Antineoplastic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Insulin-degrading enzyme,HLA class II histocompatibility antigen, DQ alpha 2 chain,HLA class II histocompatibility antigen, DQ beta 1 chain,Retinoblastoma-associated protein,Cathepsin D,Carboxypeptidase E,Neuroendocrine convertase 2,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-related protein 2,Insulin-like growth factor-binding protein 7,Synaptotagmin-like protein 4 |
| 1412 | Th1068 | Tositumomab | Heavy Chain 1: QAYLQ Full view | 1351 | IIb | Cancer | Bexxar | Galaxo Smith Kline | Sterile, pyrogen-free, clear to opalescent, colorless to slightly yellow, preservative-free solution | Intravenous(IV) administration | N.A. | Bacterial outer membrane,Lipoteichoic acid synthesis |
| 1419 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | BOTOX | Allergan | Sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strainClostridium botulinum type A | Intramuscular, intradetrusor and intradermal use | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1420 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | Dysport | Ipsen Pharmaceuticals | Sterile vial for reconstitution | Intramuscular Injection | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1421 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | Xeomin | MERZ AESTHETICS | Sterile white to off-white lyophilized powder after reconstitution with preservative-free 0.9% Saline for Injection. | Intramuscular Injection | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1422 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Pancrecarb | Digestive care US, Inc. | Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres. | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1423 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Viokace | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble in alcohol and converted to tablet form | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1424 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ULTRESA | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether and converted to Delayed-Release Capsules | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1425 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | PERTZYE | Digestive care US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether PERTZYE delayed-release capsule | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1426 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ULTRASE | Axcan Pharma | Capsules Enteric-Coated Microspheres | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1427 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ZENPEP | Aptalis Pharma US, Inc. | Delayed-Release Capsules | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1470 | Th1092 | Arcitumomab | Heavy chain 1EVKLVES Full view | 1310 | IIb | Cancer | CEA-Scan | N.A. | N.A. | N.A. | Diagnostic Agents | Vascular endothelial growth factor A,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Carcinoembryonic antigen-related cell adhesion molecule 1 |
| 1477 | Th1097 | Alglucosidase Alfa | AHPGRPRAVPTQCDVPPNSR Full view | 882 | Ic | Metabolic | LUMIZYME | Genzyme | Sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with 10.3 Ml Sterile Water for Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Cation-dependent mannose-6-phosphate receptor,Glycogen |
| 1533 | Th1112 | Natural Alpha Interferon Or Multiferon | Inteferon alpha-1: | 997 | IIa | Cancer/Infectious | Intron/ Roferon-A | N.A. | N.A. | Subcutaneous injection, Intravenous injection, Intramuscular injection | N.A. | N.A. |
| 1537 | Th1116 | Canakinumab | H-GAMMA-1 (VH(1-118) Full view | 842 | IIIb | Immunological | ILARIS | Novartis Pharmaceuticals | White, preservative-free, lyophilized powder | Subcutaneous injection | Anti-Inflammatory Agents and Monoclonal antibodies | Interleukin-1 beta |
| 1562 | Th1122 | Rilonacept | rilonacept|Homo sapi Full view | 880 | IIa | Immunological | Arcalyst | Regeneron Pharmaceuticals | Sterile, white to off-white, lyophilized powder | Subcutaneous injection | Immunosuppressive Agents | Interleukin-1 beta,Interleukin-1 alpha,Interleukin-1 receptor antagonist protein |
| 1673 | Th1160 | Satumomab Pendetide | Heavy Chain 1: QVQLQ Full view | 1299 | IV | Diagnostic Agents | OncoScint | Cytogen Corp, Lonza Biologics | N.A. | Intravenous Injection | Diagnostic Agents | Tumor-associated glycoprotein 72 (TAG-72) |
| 1785 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Bivigam | Kedrion Biopharma, Inc. | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1786 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Bivigam | Biotest Pharmaceuticals Corporation | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1788 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Carimune Nanofiltered | Csl Behring Ag | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1791 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Flebogamma Dif | GRIFOLS USA, LLC | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1793 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Gamastan | Cutter Med & Biol, Division Of Miles Canada Ltd. | liquid | Intramuscular | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1794 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Gamastan S/d | GRIFOLS USA, LLC | Injection | Intramuscular | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1795 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Hyqvia | Baxalta Us Inc. | Liquid | Intravenous infusion | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1796 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Iveegam Immuno 5000mg (iv) | Baxter Ag | NA | NA | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1805 | Th1199 | Ramucirumab | ramucirumab|Homo sap Full view | 909 | IIIc | Cancer | Cyramza | Eli Lilly and Company | Solution | Intravenous | Antineoplastic and Immunomodulating Agents | Vascular endothelial growth factor receptor 2 |
| 1832 | Th1222 | Canakinumab | H-GAMMA-1 Chain: QVQ Full view | 842 | IIa | Immunological Disorders | Ilaris | Novartis | Lyphilized powder | Subcutaneous | Antineoplastic and Immunomodulating Agents | Interleukin-1 beta |
| 1851 | Th1238 | Susoctocog alfa | AIRRYYLGAVELSWDYRQSE Full view | 1448 | Ib | Hematological Disorders | Obizur | NA | Powder and solvent for solution for injection. | Intravenous | Blood coagulation factors, Antihaemorrhagics | von Willebrand factor |